Arnold James N, Wormald Mark R, Suter David M, Radcliffe Catherine M, Harvey David J, Dwek Raymond A, Rudd Pauline M, Sim Robert B
Medical Research Council Immunochemistry Unit, University of Oxford, South Parks Road, Oxford OX1 3QU, United Kingdom.
J Biol Chem. 2005 Aug 12;280(32):29080-7. doi: 10.1074/jbc.M504528200. Epub 2005 Jun 14.
The glycoprotein IgM is the major antibody produced in the primary immune response to antigens, circulating in the serum both as a pentamer and a hexamer. Pentameric IgM has a single J chain, which is absent in the hexamer. The mu (heavy) chain of IgM has five N-linked glycosylation sites. Asn-171, Asn-332, and Asn-395 are occupied by complex glycans, whereas Asn-402 and Asn-563 are occupied by oligomannose glycans. The glycosylation of human polyclonal IgM from serum has been analyzed. IgM was found to contain 23.4% oligomannose glycans GlcNAc2Man5-9, consistent with 100% occupancy of Asn-402 and 17% occupancy of the variably occupied site at Asn-563. Mannan-binding lectin (MBL) is a member of the collectin family of proteins, which bind to oligomannose and GlcNAc-terminating structures. A commercial affinity chromatography resin containing immobilized MBL has been reported to be useful for partial purification of mouse and also human IgM. Human IgM glycoforms that bind to immobilized MBL were isolated; these accounted for only 20% of total serum IgM. Compared with total serum IgM, the MBL-binding glycoforms contained 97% more GlcNAc-terminating structures and 8% more oligomannose structures. A glycosylated model of pentameric IgM was constructed, and from this model, it became evident that IgM has two distinct faces, only one of which can bind to antigen, as the J chain projects from the non-antigen-binding face. Antigen-bound IgM does not bind to MBL, as the target glycans appear to become inaccessible once IgM has bound antigen. Antigen-bound IgM pentamers therefore do not activate complement via the lectin pathway, but MBL might have a role in the clearance of aggregated IgM.
糖蛋白IgM是在对抗原的初次免疫应答中产生的主要抗体,以五聚体和六聚体形式在血清中循环。五聚体IgM有一条单一的J链,六聚体中不存在。IgM的μ(重)链有五个N-连接糖基化位点。天冬酰胺-171、天冬酰胺-332和天冬酰胺-395被复合聚糖占据,而天冬酰胺-402和天冬酰胺-563被低聚甘露糖聚糖占据。已对血清中人多克隆IgM的糖基化进行了分析。发现IgM含有23.4%的低聚甘露糖聚糖GlcNAc2Man5 - 9,这与天冬酰胺-402的100%占据以及天冬酰胺-563可变占据位点的17%占据情况一致。甘露聚糖结合凝集素(MBL)是凝集素家族蛋白质的成员,可结合低聚甘露糖和以GlcNAc结尾的结构。据报道,一种含有固定化MBL的商业亲和层析树脂可用于小鼠IgM以及人IgM的部分纯化。分离出了与固定化MBL结合的人IgM糖型;这些仅占血清总IgM的20%。与血清总IgM相比,与MBL结合的糖型含有多97%的以GlcNAc结尾的结构和多8%的低聚甘露糖结构。构建了五聚体IgM的糖基化模型,并从该模型中明显看出,IgM有两个不同的面,其中只有一个能结合抗原,因为J链从非抗原结合面伸出。结合抗原的IgM不与MBL结合,因为一旦IgM结合抗原,目标聚糖似乎就变得无法接近。因此,结合抗原的IgM五聚体不会通过凝集素途径激活补体,但MBL可能在聚集IgM的清除中起作用。